Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry
ObjectiveChronic hepatitis C virus infection is associated with a significant health burden. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. The introduction of direct-acting antivirals (DAA) has led to an increase in sustained virologic response rates (SV
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
February 2019
|
| In: |
European journal of gastroenterology & hepatology
Year: 2019, Jahrgang: 31, Heft: 2, Pages: 230-240 |
| ISSN: | 1473-5687 |
| DOI: | 10.1097/MEG.0000000000001283 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1097/MEG.0000000000001283 |
| Verfasserangaben: | Kathrin Krüger, Christian Krauth, Siegbert Rossol, Stefan Mauss, Klaus Boeker, Tobias Müller, Hartwig Klinker, Anita Pathil, Renate Heyne, Jona Stahmeyer, and Collaborators DHC-R |
| Zusammenfassung: | ObjectiveChronic hepatitis C virus infection is associated with a significant health burden. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. The introduction of direct-acting antivirals (DAA) has led to an increase in sustained virologic response rates (SV |
|---|---|
| Beschreibung: | Gesehen am 29.11.2019 |
| Beschreibung: | Online Resource |
| ISSN: | 1473-5687 |
| DOI: | 10.1097/MEG.0000000000001283 |